AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36004715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis HN019 (n=64)
Number of subjects: 192
Study 36004715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus HN001 (n=64)
Number of subjects: 192
Study 36004715 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=64)
Number of subjects: 192
Study 34418549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ALA-PDT treatment
Number of subjects: 7
Study 34418549 — intervention group
Group type: COMPARATOR
Intervention: Red-light treatment
Number of subjects: 7
Study 33775200 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 20
Study 33775200 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 32303515 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE plus treatment‐as‐usual (TAU)
Number of subjects: 51
Study 32303515 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 51
Study 35152272 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multimodal (aerobic and resistance) exercise (EX)
Number of subjects: 25
Study 35152272 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention serum from EX
Number of subjects: 25
Study 35152272 — intervention group
Group type: COMPARATOR
Intervention: Self-directed exercise control group (CON)
Number of subjects: 25
Study 34221078 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward Walking (BW) combined with conventional treatments
Number of subjects: 32
Study 34221078 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments alone (Control Group)
Number of subjects: 32
Study 36223293 — intervention group
Group type: COMPARATOR
Intervention: Disposable ports
Number of subjects: 473
Study 36223293 — intervention group
Group type: EXPERIMENTAL
Intervention: Reprocessed disposable ports
Number of subjects: 473
Study 36250845 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato extract for 49 days
Number of subjects: 184
Study 36250845 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 49 days
Number of subjects: 184
Study 33733479 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise rehabilitation program (2 days/week, 60 minutes, personalized, one-on-one, resistance-based training)
Number of subjects: 80
Study 33733479 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise rehabilitation program
Number of subjects: 80
Study 33733479 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study 32475836 — intervention group
Group type: EXPERIMENTAL
Intervention: Salud y Vida 2.0 (enhanced version)
Number of subjects: 353
Study 32475836 — intervention group
Group type: COMPARATOR
Intervention: Salud y Vida 1.0 (control program)
Number of subjects: 353
Study 35915346 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned open-label placebo (COLP)
Number of subjects: 18
Study 33222405 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrality measures (strength, betweenness, closeness) of mothers' baseline factors
Number of subjects: 448
Study 33222405 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength at baseline
Number of subjects: 448
Study 32069450 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 54
Study 32069450 — intervention group
Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 54
Study 34433114 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery‐Experiential elaboration condition (n=27)
Number of subjects: 81
Study 34433114 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal‐Reasoning elaboration condition (n=28)
Number of subjects: 81
Study 34433114 — intervention group
Group type: COMPARATOR
Intervention: Scheduling‐only Control condition (n=26)
Number of subjects: 81
Study 35220371 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 72
Study 35220371 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RES)
Number of subjects: 72
Study 32505495 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen (IVIB)
Number of subjects: 344
Study 32505495 — intervention group
Group type: COMPARATOR
Intervention: Placebo or comparator medication
Number of subjects: 344
Study 35542976 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical nomogram for predicting NAFLD
Number of subjects: 14251
Study 35723855 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic activity (MoIA)
Number of subjects: 60
Study 35723855 — intervention group
Group type: COMPARATOR
Intervention: Mild-intensity aerobic activity (MIA)
Number of subjects: 60
Study 35723855 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study 34652287 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB+RPV long-acting Q2M
Number of subjects: 97
Study 34652287 — intervention group
Group type: COMPARATOR
Intervention: dolutegravir/RPV
Number of subjects: 97
Study 33607104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg/day from day 1-5, then 10 mg/day from day 6-10)
Number of subjects: 50
Study 33607104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 50
Study 33607104 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 34281901 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with simple congenital ptosis
Number of subjects: 81
Study 34281901 — intervention group
Group type: COMPARATOR
Intervention: Controls (age-matched and gender-matched)
Number of subjects: 81
Study 33843971 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted interventions including site-based clinical leads, stakeholder meetings, a train-the-trainer workshop, targeted educational delivery, and audit and feedback.
Number of subjects: 3727
Study 33843971 — intervention group
Group type: COMPARATOR
Intervention: Passive dissemination of an evidence-based bronchiolitis guideline (control group).
Number of subjects: 3727
Study 36328879 — intervention group
Group type: EXPERIMENTAL
Intervention: CORBEVAX™ vaccine
Number of subjects: 100
Study 36328879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34554865 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 3104
Study 34554865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 3104
Study 34554865 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3104
Study 32462261 — intervention group
Group type: EXPERIMENTAL
Intervention: AC Paclitaxel (P)
Number of subjects: 395
Study 32462261 — intervention group
Group type: EXPERIMENTAL
Intervention: AC Docetaxel (D)
Number of subjects: 395
Study 32462261 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX
Number of subjects: 395
Study 32462261 — intervention group
Group type: EXPERIMENTAL
Intervention: DTX
Number of subjects: 395
Study 32462261 — intervention group
Group type: EXPERIMENTAL
Intervention: CIA group
Number of subjects: 395
Study 32462261 — intervention group
Group type: EXPERIMENTAL
Intervention: CIA
Number of subjects: 395
Study 34212533 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 604
Study 34212533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 34337189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile acuity training using the Imprint Tactile Acuity Device (iTAD) for four weeks.
Number of subjects: 36
Study 34337189 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention using a de-activated TENS machine (iTENS) for four weeks.
Number of subjects: 36
Study 34558338 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 101
Study 34558338 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week symptom reporting
Number of subjects: 101
Study 34558338 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing susto
Number of subjects: 101
Study 33631065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg per kilogram of body weight)
Number of subjects: 803
Study 33631065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab (400 mg)
Number of subjects: 803
Study 33631065 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 803
Study 33631065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled interleukin‐6 receptor antagonists (tocilizumab and sarilumab)
Number of subjects: 803
Study 32596348 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (300 mg of caffeine in 25 mL of water)
Number of subjects: 10
Study 32596348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose in 25 mL of water)
Number of subjects: 10
Study 36081615 — intervention group
Group type: EXPERIMENTAL
Intervention: Home activity control system (Beprevent)
Number of subjects: 20
Study 36081615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 33169543 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐PTFE membrane (test)
Number of subjects: 12
Study 33169543 — intervention group
Group type: COMPARATOR
Intervention: d‐PTFE membrane (control)
Number of subjects: 12
Study 33169543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both membranes (e‐PTFE and d‐PTFE)
Number of subjects: 12
Study 34601588 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended information about the CT examination including visualization of individual coronary calcium score images
Number of subjects: 92
Study 34601588 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no extended information or examination result)
Number of subjects: 92
Study 34445043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tartaric acid (biomarker of wine consumption)
Number of subjects: 230
Study 34445043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tartaric acid
Number of subjects: 230
Study 32123143 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO percutaneous coronary intervention (PCI)
Number of subjects: 22
Study 32123143 — intervention group
Group type: COMPARATOR
Intervention: No revascularization of the CTO
Number of subjects: 22
Study 36306807 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus educational intervention
Number of subjects: 153
Study 36306807 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus behavioural parent training
Number of subjects: 153
Study 36306807 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus educational intervention
Number of subjects: 153
Study 32115035 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid content in crop milk from day 1 (R1) to day 25 (R25) of chick rearing
Number of subjects: 84
Study 32115035 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid content in plasma
Number of subjects: 84
Study 32115035 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA abundances of AA transporters in male crops
Number of subjects: 84
Study 32115035 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA abundances of AA transporters in female crops
Number of subjects: 84
Study 32115035 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expressions of enzymes involved in AA synthesis
Number of subjects: 84
Study 36316911 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute intermittent stretching (SS2)
Number of subjects: 30
Study 36316911 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-minute intermittent stretching (SS4)
Number of subjects: 30
Study 36316911 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-minute intermittent stretching (SS8)
Number of subjects: 30
Study 33751155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 16
Study 33751155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32195960 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus Laser Acupuncture (LA)
Number of subjects: 50
Study 32195960 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) plus sham Laser Acupuncture (LA) without laser output
Number of subjects: 50
Study 35400624 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile vaginal gel 5%
Number of subjects: 96
Study 35400624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 96
Study 35400624 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal gel
Number of subjects: 96
Study 34226233 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) for soil-transmitted helminths, costing averaged US$1.14 per person per round in the first year of the trial, net of drugs.
Number of subjects: 0
Study 34226233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesised at-scale routine implementation scenario for cMDA, estimated US$0.11 per person treated per round.
Number of subjects: 0
Study 35417763 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation (MHF) - 70 Gy in 28 daily fractions
Number of subjects: 78
Study 35417763 — intervention group
Group type: COMPARATOR
Intervention: Ultrahypofractionation (UHF) - 36.25 Gy in 5 weekly fractions
Number of subjects: 78
Study 33554587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation
Number of subjects: 450
Study 33554587 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose vitamin D3 supplementation
Number of subjects: 450
Study 33554587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D3 supplementation
Number of subjects: 450
Study 32135010 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol genetic score (1760 variants)
Number of subjects: 9000
Study 32135010 — intervention group
Group type: EXPERIMENTAL
Intervention: Main-effect genetic risk score for LDL cholesterol
Number of subjects: 9000
Study 32135010 — intervention group
Group type: EXPERIMENTAL
Intervention: Downstream disease outcomes
Number of subjects: 9000
Study 34376277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild anemia group (Hb 10≤ Hb <13 g/dl for men and 10≤ Hb <12 g/dl for women)
Number of subjects: 1677
Study 34376277 — intervention group
Group type: COMPARATOR
Intervention: Non-anemia group (Hb ≥13 g/dl for men and Hb ≥12 g/dl for women)
Number of subjects: 1677
Study 32669371 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) combined with pembrolizumab
Number of subjects: 36
Study 32669371 — intervention group
Group type: COMPARATOR
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 36
Study 32669371 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 36
Study 36189549 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Glyceryl Trinitrate (GTN) ointment
Number of subjects: 94
Study 36189549 — intervention group
Group type: COMPARATOR
Intervention: Lateral Internal Sphincterotomy (LIS)
Number of subjects: 94
Study 34157116 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS (measured in μmol/L)
Number of subjects: 0
Study 34157116 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 0
Study 34589887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous cervical VNS (tcVNS)
Number of subjects: 30
Study 34589887 — intervention group
Group type: COMPARATOR
Intervention: Sham tcVNS
Number of subjects: 30
Study 34589887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tcVNS
Number of subjects: 30
Study 36233711 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with AF and CAD
Number of subjects: 461
Study 36233711 — intervention group
Group type: COMPARATOR
Intervention: Men with AF and CAD
Number of subjects: 461
Study 36233711 — intervention group
Group type: COMPARATOR
Intervention: Both genders
Number of subjects: 461
Study 33980157 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (use of five or more medications)
Number of subjects: 150
Study 33980157 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age group (18‐29 years)
Number of subjects: 150
Study 33980157 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 150
Study 33980157 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-consumption of whole grains
Number of subjects: 150
Study 36345818 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM‐C with porcine collagen matrix (CM)
Number of subjects: 42
Study 33451904 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5T MRI
Number of subjects: 160
Study 33451904 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0T MRI
Number of subjects: 160
Study 33451904 — intervention group
Group type: COMPARATOR
Intervention: Static Ultrasound (US)
Number of subjects: 160
Study 33451904 — intervention group
Group type: COMPARATOR
Intervention: All modalities (1.5T MRI, 3.0T MRI, Static US)
Number of subjects: 160
Study 33451904 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 160
Study 35206179 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 inhalation, 2 × 60 min/day for 14 days
Number of subjects: 50
Study 35206179 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 50
Study 34067980 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent stimulation
Number of subjects: 28
Study 34067980 — intervention group
Group type: COMPARATOR
Intervention: False microcurrent stimulation (Control)
Number of subjects: 28
Study 32327254 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 1095
Study 32327254 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab
Number of subjects: 1095
Study 32327254 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab therapy
Number of subjects: 1095
Study 32327254 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN ranibizumab therapy
Number of subjects: 1095
Study 32327254 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose treatment
Number of subjects: 1095
Study 32327254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid/function correlation
Number of subjects: 1095
Study 35144024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical test (FIT) kits
Number of subjects: 0
Study 35144024 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy invitations
Number of subjects: 0
Study 34000236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine adsorption using the CytoSorb device
Number of subjects: 34
Study 34000236 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cytokine adsorption)
Number of subjects: 34
Study 34000236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine adsorption
Number of subjects: 34
Study 32481240 — intervention group
Group type: EXPERIMENTAL
Intervention: Halliwick (Hallw)
Number of subjects: 30
Study 32481240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Plyometric Exercise (APE)
Number of subjects: 30
Study 35463130 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS therapy plus standard of care (SoC), 2 consecutive 2-min doses of nVNS 3 times daily as prophylaxis.
Number of subjects: 110
Study 35463130 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS therapy plus standard of care (SoC)
Number of subjects: 110
Study 35463130 — intervention group
Group type: COMPARATOR
Intervention: standard of care (SoC) alone
Number of subjects: 110
Study 33949703 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive sexual and reproductive health education program (two 40-min sessions)
Number of subjects: 469
Study 33949703 — intervention group
Group type: COMPARATOR
Intervention: Usual mode of sexual and reproductive health education
Number of subjects: 469
Study 33009629 — intervention group
Group type: EXPERIMENTAL
Intervention: Etifoxine 150 mg/day for 12 weeks
Number of subjects: 179
Study 33009629 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam 1 mg/day for 12 weeks
Number of subjects: 179
Study 35120656 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with ustekinumab (6 mg/kg IV at baseline, 90 mg SC at week 8, and potential escalation to every 4 weeks based on SES-CD improvement)
Number of subjects: 440
Study 35120656 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with ustekinumab
Number of subjects: 440
Study 35120656 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care strategy with ustekinumab (6 mg/kg IV at baseline, 90 mg SC at week 8, and potential escalation per European labelling)
Number of subjects: 440
Study 35120656 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care strategy with ustekinumab
Number of subjects: 440
Study 33246270 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated nomogram
Number of subjects: 124
Study 33246270 — intervention group
Group type: COMPARATOR
Intervention: Clinical nomogram
Number of subjects: 124
Study 33246270 — intervention group
Group type: COMPARATOR
Intervention: Radiomics nomogram
Number of subjects: 124
Study 32669099 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (100 ml twice daily starting from 3 days before the operation)
Number of subjects: 0
Study 32669099 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA 1.5 g twice daily starting from 3 days before the operation)
Number of subjects: 0
Study 32669099 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA 1.5 g administered 30 min before the operation
Number of subjects: 0
Study 32669099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Normal saline and TXA)
Number of subjects: 0
Study 36414207 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (DHI) including digital monitoring of sleep, meals, and physical activity plus weekly motivational health coaching
Number of subjects: 200
Study 36414207 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) consisting of weekly telephone calls and similar assessment schedules
Number of subjects: 200
Study 33723110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based pulmonary rehabilitation (PR) program
Number of subjects: 58
Study 33723110 — intervention group
Group type: COMPARATOR
Intervention: Self-management pulmonary rehabilitation (PR) program
Number of subjects: 58
Study 32635494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oceanix (OCX) 25 mg for 14 days
Number of subjects: 14
Study 32635494 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + OCX 2 (5.1 mg/day)
Number of subjects: 14